Foresite Labs Incubated Company Vignette Bio Enters License Agreement with EpimAb to Develop EMB-06

Gunderson Dettmer represented the Foresite Labs incubated company, Vignette Bio, in the announcement of Vignette and EpimAb entering into a licensing agreement for EpimAb’s BCMA-targeting T-cell engager (TCE) EMB-06. Vignette Bio focuses on innovative therapies to address immunology and inflammation associated diseases and EpimAb is a clinical stage biopharmaceutical company specializing in the discovery and development of multi-specific antibodies for diseases with high unmet needs.

Under this agreement, EpimAb will grant Vignette the exclusive rights to develop and commercialize EMB-06 outside of Greater China (mainland China, Hong Kong, Macau and Taiwan), while EpimAb shall retain the rights to EMB-06 in Greater China. EpimAb will receive total upfront considerations of $60 million in cash and equity of Vignette, and will be eligible to receive up to $575 million development, regulatory and commercial milestones, plus royalties on net sales.

In the announcement of the collaboration, managing director at Foresite Capital and lead investor at Vignette Michael Rome said,  “Emerging clinical data using B-cell depletion in autoimmune diseases has shown compelling results. EMB-06 is a promising clinical asset and we look forward to building a leading company focused on T-cell engagers for autoimmune diseases.”

The Gunderson Dettmer team was led by Brendan McCarthy and included Anthony Farnesi.

Companies
Foresite Labs
Vignette Bio
EpimAb